Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

NCT02396953 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
28
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Ipsen